Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK) and Tandem Diabetes Care (TNDM)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cytokinetics (CYTK – Research Report) and Tandem Diabetes Care (TNDM – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cytokinetics (CYTK)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics today and set a price target of $136.00. The company’s shares closed last Friday at $67.94.
According to TipRanks.com, Pantginis is a 4-star analyst with an average return of
Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $92.14, which is a 36.1% upside from current levels. In a report issued on February 8, J.P. Morgan also maintained a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
Tandem Diabetes Care (TNDM)
Truist Financial analyst Richard Newitter reiterated a Hold rating on Tandem Diabetes Care today and set a price target of $27.00. The company’s shares closed last Friday at $24.57.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of
Tandem Diabetes Care has an analyst consensus of Moderate Buy, with a price target consensus of $29.00, which is a 27.5% upside from current levels. In a report issued on February 20, Bank of America Securities also upgraded the stock to Hold with a $30.00 price target.
